Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Editas Deal Opens Allergan's Eyes To CRISPR Opportunities

Executive Summary

Editas' stock shot up 11% by mid-morning on March 14, after the gene therapy company announced a deal with Allergan worth $90m up front for "cool" CRISPR programs in ocular indications. However, the lead therapy included in the deal offers potentially limited profitability in a small orphan space.

Advertisement

Related Content

Deals Of The Year: Cast Your Vote For Top Alliance Of 2017
Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
Allergan's Fishing For Deals, But Don't Expect A Big Catch

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel